Source link : https://www.newshealth.biz/health-news/sglt2-inhibitor-carry-over-benefits-last-how-long/
SAN DIEGO — Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During a median 2 years of post-trial follow-up, the risk of kidney disease progression or cardiovascular death remained 13% lower for patients who had been randomized to empagliflozin […]
Author : News Health
Publish date : 2024-10-29 15:42:18
Copyright for syndicated content belongs to the linked Source.
